Skip to main content

Myriad to Buy Back $200M in Shares

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Monday that its board has approved a new $200 million stock repurchase program.

The board had previously approved a $100 million stock buyback program in March.

Repurchases under the new program will be made through open market or privately negotiated purchases. The amount and timing of the repurchases will depend on a number of factors including business and market conditions, trading restrictions, acquisition activity, and stock price, the Salt Lake City company said.

As of June 30, Myriad had more than $417 million in cash, cash equivalents, and marketable securities.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.